Aparna Ahuja - Net Worth and Insider Trading

Aparna Ahuja Net Worth

The estimated net worth of Aparna Ahuja is at least $8,952 dollars as of 2024-05-15. Aparna Ahuja is the Chief Medical Officer of T2 Biosystems Inc and owns about 2,152 shares of T2 Biosystems Inc (TTOO) stock worth over $8,952. Details can be seen in Aparna Ahuja's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Aparna Ahuja has not made any transactions after 2022-01-06 and currently still holds the listed stock(s).

Transaction Summary of Aparna Ahuja

To

Aparna Ahuja Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aparna Ahuja owns 1 companies in total, including T2 Biosystems Inc (TTOO) .

Click here to see the complete history of Aparna Ahuja’s form 4 insider trades.

Insider Ownership Summary of Aparna Ahuja

Ticker Comapny Transaction Date Type of Owner
TTOO T2 Biosystems Inc 2022-01-06 Chief Medical Officer

Aparna Ahuja Latest Holdings Summary

Aparna Ahuja currently owns a total of 1 stock. Aparna Ahuja owns 2,152 shares of T2 Biosystems Inc (TTOO) as of January 6, 2022, with a value of $8,952.

Latest Holdings of Aparna Ahuja

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TTOO T2 Biosystems Inc 2022-01-06 2,152 4.16 8,952

Holding Weightings of Aparna Ahuja


Aparna Ahuja Form 4 Trading Tracker

According to the SEC Form 4 filings, Aparna Ahuja has made a total of 1 transactions in T2 Biosystems Inc (TTOO) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in T2 Biosystems Inc is the sale of 1,240 shares on January 6, 2022, which brought Aparna Ahuja around $29,754.

Insider Trading History of Aparna Ahuja

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Aparna Ahuja Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Aparna Ahuja Ownership Network

Ownership Network List of Aparna Ahuja

No Data

Ownership Network Relation of Aparna Ahuja


Aparna Ahuja Owned Company Details

What does T2 Biosystems Inc do?

Who are the key executives at T2 Biosystems Inc?

Aparna Ahuja is the Chief Medical Officer of T2 Biosystems Inc. Other key executives at T2 Biosystems Inc include 10 percent owner Cr Group L.p. , 10 percent owner Crg Partners Iii - Parallel Fund (a) L.p. , and 10 percent owner Crg Partners Iii L.p. .

T2 Biosystems Inc (TTOO) Insider Trades Summary

Over the past 18 months, Aparna Ahuja made no insider transaction in T2 Biosystems Inc (TTOO). Other recent insider transactions involving T2 Biosystems Inc (TTOO) include a net sale of 48,345,798 shares made by Cr Group L.p. , a net sale of 3,969 shares made by Michael Terrence Gibbs , and a net sale of 1,074 shares made by Brett A. Giffin .

In summary, during the past 3 months, insiders sold 0 shares of T2 Biosystems Inc (TTOO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 48,363,307 shares of T2 Biosystems Inc (TTOO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 48,363,307 shares.

T2 Biosystems Inc (TTOO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

T2 Biosystems Inc Insider Transactions

No Available Data

Aparna Ahuja Mailing Address

Above is the net worth, insider trading, and ownership report for Aparna Ahuja. You might contact Aparna Ahuja via mailing address: 101 Hartwell Avenue, Lexington Ma 02421.

Discussions on Aparna Ahuja

No discussions yet.